Skip to content
Screener

Inhibrx Biosciences, Inc. INBX Q3 2025 earnings

Reported November 14, 2025 · Before market open

Revenue-
EPS-$2.28Miss by $0.20
EPS estimate-$2.08

Next report

Nov 13, 2026 (in 2 months)
Revenue estimate$1.9M
EPS estimate-$2.50

Financials

Q3 2025

Income statement

See full
Revenue-—
Operating income-$33.8M+27.7%
Net income-$35.3M+19.6%
EPS (diluted)-$2.28+19.7%

Balance sheet

See full
Cash & equivalents$153.1M-22.0%
Total debt$106.9M+5,726%
Total equity$36.8M-79.4%
Total assets$177.5M-20.3%

Cash flow

See full
Operating cash flow-$33.8M-11.7%
CapEx$10.0K-96.0%
Free cash flow-$33.8M-10.8%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$487.87M+115%
Enterprise value$441.69M+1,272%
P/S348.5×+218×

Profitability

See full
Operating margin-11,002.1%-3,589pp
Net margin-7,658.6%-102,343pp
FCF margin-10,245.6%-1,474pp

Returns & leverage

See full
Return on equity-99.6%-1,166pp
Debt / equity2.9×+2.9×
Current ratio4.5×-0.2×

FAQ

When did Inhibrx Biosciences, Inc. report Q3 2025 earnings?
Inhibrx Biosciences, Inc. (INBX) reported Q3 2025 earnings on November 14, 2025 before market open.
What were Inhibrx Biosciences, Inc.'s Q3 2025 revenue and EPS?
Inhibrx Biosciences, Inc. reported revenue of - and eps of $-2.28 for Q3 2025.
Did Inhibrx Biosciences, Inc. beat estimates in Q3 2025?
EPS missed the consensus estimate of $-2.08 by $0.20.
How did Inhibrx Biosciences, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 19.7% from $-2.84.
Where can I find Inhibrx Biosciences, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0002007919-25-000094) and the 10-Q periodic report (0002007919-25-000093) directly on SEC EDGAR. The filing index links above go to sec.gov.